This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Antibody Engineering & Therapeutics US

Hurry! $300 Savings Ends In:

  • 00
    Days
  • 00
    Hrs
  • 00
    Mins
  • 00
    Secs
December 4 - 8, 2022
Marriott Marquis San DiegoLive In-Person Event: December 4 - 8, 2022

Nicolas Fischer, PhD
CEO at Light Chain Bioscience

Profile

After obtaining a PhD in molecular biology, Nicolas joined the group of Greg Winter (2018 Nobel prize for chemistry) at the Medical Research Council in Cambridge (UK) to work on in vitro evolution of proteins and antibody engineering.

At Novimmune since 2002, he led several therapeutic antibody programs. Then, as the Head of Research, he focused on the development of the κλ body bispecific antibody platform which is now the core technology of Light Chain Bioscience where he acts as CEO.

Agenda Sessions

  • Varying Affinity, Avidity and Fc Domain of Anti-CD47 bispecific antibodies enabling different anti-tumoral modes of action

    8:15am